7 tesla magnetic resonance imaging: A closer look at substantia nigra anatomy in Parkinson's disease

Movement Disorders

Volumn 29, Issue 13, 2014, Pages 1574-1581

  Lehéricy, Stéphane ^a,b,c,d   Bardinet, Eric ^a,b   Poupon, Cyril ^e   Vidailhet, Marie ^b,c   François, Chantal ^b  

^a INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c ICM Team Control of Normal and Abnormal Movement   (France)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e DIF   (France)

Author keywords

Iron; Neuromelanin; Nigrosome; Substantia nigra pars compacta; Substantia nigra pars reticulata

Indexed keywords

FEMALE; HUMAN; IMAGE PROCESSING; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; PATHOLOGY; SUBSTANTIA NIGRA;

FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; PARKINSON DISEASE; SUBSTANTIA NIGRA;

EID: 84911093882     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.26043     Document Type: Article

References (65)

1. Olszewski J, Baxter D. Cytoarchitecture of the Human Brain Stem. 2nd ed. Basel: Karger, 1954.
2. Dahlstrom A, Fuxe K. Localization of monoamines in the lower brain stem. Experientia 1964;20:398-399.
3. Gibb WR. Melanin, tyrosine hydroxylase, calbindin and substance P in the human midbrain and substantia nigra in relation to nigrostriatal projections and differential neuronal susceptibility in Parkinson's disease. Brain Res 1992;581:283-291.
4. Haber SN, Groenewegen HJ. Interrelationship of the distribution of neuropeptides and tyrosine hydroxylase immunoreactivity in the human substantia Nigra. J Comp Neurol 1989;290:53-68.
5. Damier P, Hirsch EC, Agid Y, Graybiel AM. The substantia nigra of the human brain. I. Nigrosomes and the nigral matrix, a compartmental organization based on calbindin D(28K) immunohistochemistry. Brain 1999;122:1421-1436.
6. Yamada T, McGeer PL, Baimbridge KG, McGeer EG. Relative sparing in Parkinson's disease of substantia nigra dopamine neurons containing calbindin-D28K. Brain Res 1990;526:303-307.
7. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991;114:2283-2301.
8. Lynd-Balta E, Haber SN. The organization of midbrain projections to the striatum in the primate: sensorimotor-related striatum versus ventral striatum. Neuroscience 1994;59:625-640.
9. Gaspar P, Stepniewska I, Kaas JH. Topography and collateralization of the dopaminergic projections to motor and lateral prefrontal cortex in owl monkeys. J Comp Neurol 1992;325:1-21.
10. Williams SM, Goldman-Rakic PS. Widespread origin of the primate mesofrontal dopamine system. Cereb Cortex 1998;8:321-345.
11. Bisaglia M, Mammi S, Bubacco L. Kinetic and structural analysis of the early oxidation products of dopamine: analysis of the interactions with alpha-synuclein. J Biol Chem 2007;282:15597-15605.
12. Mann DM, Yates PO. Lipoprotein pigments: their relationship to ageing in the human nervous system. II. The melanin content of pigmented nerve cells. Brain 1974;97:489-498.
13. Bogerts B. A brainstem atlas of catecholaminergic neurons in man, using melanin as a natural marker. J Comp Neurol 1981;197:63-80.
14. Cotzias GC, Papavasiliou PS, Vanwoert MH, Sakamoto A. Melanogenesis and extrapyramidal diseases. Fed Proc 1964;23:713-718.
15. Graham DG. On the origin and significance of neuromelanin. Arch Pathol Lab Med 1979;103:359-362.
16. Cowen D. The melanoneurons of the human cerebellum (nucleus pigmentosus cerebellaris) and homologues in the monkey. J Neuropathol Exp Neurol 1986;45:205-221.
17. Zecca L, Swartz HM. Total and paramagnetic metals in human substantia nigra and its neuromelanin. J Neural Transm Park Dis Dement Sect 1993;5:203-213.
18. Zecca L, Pietra R, Goj C, Mecacci C, Radice D, Sabbioni E. Iron and other metals in neuromelanin, substantia nigra, and putamen of human brain. J Neurochem 1994;62:1097-1101.
19. Swartz HM, Sarna T, Zecca L. Modulation by neuromelanin of the availability and reactivity of metal ions. Ann Neurol 1992;32(Suppl):S69-S75.
20. Morris CM, Candy JM, Oakley AE, Bloxham CA, Edwardson JA. Histochemical distribution of non-haem iron in the human brain. Acta Anat (Basel) 1992;144:235-257.
21. Dormont D, Ricciardi KG, Tande D, et al. Is the subthalamic nucleus hypointense on T2-weighted images? A correlation study using MR imaging and stereotactic atlas data. AJNR Am J Neuroradiol 2004;25:1516-1523.
22. Francois C, Nguyen-Legros J, Percheron G. Topographical and cytological localization of iron in rat and monkey brains. Brain Res 1981;215:317-322.
23. Zecca L, Youdim MB, Riederer P, Connor JR, Crichton RR. Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci 2004;5:863-873.
24. Kordower JH, Olanow CW, Dodiya HB, et al. Disease duration and the integrity of the nigrostriatal system in Parkinson's disease. Brain 2013;136:2419-2431.
25. Jellinger KA. Neuropathology of sporadic Parkinson's disease: evaluation and changes of concepts. Mov Disord 2012;27:8-30.
26. Damier P, Hirsch EC, Agid Y, Graybiel AM. The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain 1999;122:1437-1448.
27. McRitchie DA, Cartwright HR, Halliday GM. Specific A10 dopaminergic nuclei in the midbrain degenerate in Parkinson's disease. Exp Neurol 1997;144:202-213.
28. Hirsch E, Graybiel AM, Agid YA. Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature 1988;334:345-348.
29. Hirsch EC, Brandel JP, Galle P, Javoy-Agid F, Agid Y. Iron and aluminum increase in the substantia nigra of patients with Parkinson's disease: an X-ray microanalysis. J Neurochem 1991;56:446-451.
30. Dexter DT, Wells FR, Lees AJ, et al. Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J Neurochem 1989;52:1830-1836.
31. Riederer P, Dirr A, Goetz M, Sofic E, Jellinger K, Youdim MB. Distribution of iron in different brain regions and subcellular compartments in Parkinson's disease. Ann Neurol 1992;(32 Suppl):S101-S104.
32. Jellinger K, Kienzl E, Rumpelmair G, et al. Iron-melanin complex in substantia nigra of parkinsonian brains: an x-ray microanalysis. J Neurochem 1992;59:1168-1171.
33. Good PF, Olanow CW, Perl DP. Neuromelanin-containing neurons of the substantia nigra accumulate iron and aluminum in Parkinson's disease: a LAMMA study. Brain Res 1992;593:343-346.
34. Jellinger KA, Kienzl E, Rumpelmaier G, et al. Iron and ferritin in substantia nigra in Parkinson's disease. Adv Neurol 1993;60:267-272.
35. Gerlach M, Double KL, Youdim MB, Riederer P. Potential sources of increased iron in the substantia nigra of parkinsonian patients. J Neural Transm Suppl 2006:133-142.
36. Drayer BP. Imaging of the aging brain. Part II. Pathologic conditions. Radiology 1988;166:797-806.
37. Rutledge JN, Hilal SK, Silver AJ, Defendini R, Fahn S. Study of movement disorders and brain iron by MR. AJR Am J Roentgenol 1987;149:365-379.
38. Hirsch WL, Kemp SS, Martinez AJ, Curtin H, Latchaw RE, Wolf G. Anatomy of the brainstem: correlation of in vitro MR images with histologic sections. AJNR Am J Neuroradiol 1989;10:923-928.
39. Flannigan BD, Bradley WG, Jr., Mazziotta JC, et al. Magnetic resonance imaging of the brainstem: normal structure and basic functional anatomy. Radiology 1985;154:375-383.
40. Drayer BP, Olanow W, Burger P, Johnson GA, Herfkens R, Riederer S. Parkinson plus syndrome: diagnosis using high field MR imaging of brain iron. Radiology 1986;159:493-498.
41. Braffman BH, Grossman RI, Goldberg HI, et al. MR imaging of Parkinson disease with spin-echo and gradient-echo sequences. AJR Am J Roentgenol 1989;152:159-165.
42. Stern MB, Braffman BH, Skolnick BE, Hurtig HI, Grossman RI. Magnetic resonance imaging in Parkinson's disease and parkinsonian syndromes. Neurology 1989;39:1524-1526.
43. Pujol J, Junque C, Vendrell P, Grau JM, Capdevila A. Reduction of the substantia nigra width and motor decline in aging and Parkinson's disease. Arch Neurol 1992;49:1119-1122.
44. Duguid JR, De La Paz R, DeGroot J. Magnetic resonance imaging of the midbrain in Parkinson's disease. Ann Neurol 1986;20:744-747.
45. Sasaki M, Shibata E, Tohyama K, et al. Neuromelanin magnetic resonance imaging of locus ceruleus and substantia nigra in Parkinson's disease. Neuroreport 2006;17:1215-1218.
46. Keren NI, Lozar CT, Harris KC, Morgan PS, Eckert MA. In vivo mapping of the human locus coeruleus. Neuroimage 2009;47:1261-1267.
47. Enochs WS, Petherick P, Bogdanova A, Mohr U, Weissleder R. Paramagnetic metal scavenging by melanin: MR imaging. Radiology 1997;204:417-423.
48. Oikawa H, Sasaki M, Tamakawa Y, Ehara S, Tohyama K. The substantia nigra in Parkinson disease: proton density-weighted spin-echo and fast short inversion time inversion-recovery MR findings. AJNR Am J Neuroradiol 2002;23:1747-1756.
49. Peran P, Cherubini A, Assogna F, et al. Magnetic resonance imaging markers of Parkinson's disease nigrostriatal signature. Brain 2010;133:3423-3433.
50. Lehericy S, Sharman MA, Dos Santos CL, Paquin R, Gallea C. Magnetic resonance imaging of the substantia nigra in Parkinson's disease. Mov Disord 2012;27:822-830.
51. Minati L, Grisoli M, Carella F, De Simone T, Bruzzone MG, Savoiardo M. Imaging degeneration of the substantia nigra in Parkinson disease with inversion-recovery MR imaging. AJNR Am J Neuroradiol 2007;28:309-313.
52. Hutchinson M, Raff U, Lebedev S. MRI correlates of pathology in parkinsonism: segmented inversion recovery ratio imaging (SIRRIM). Neuroimage 2003;20:1899-1902.
53. Menke RA, Scholz J, Miller KL, et al. MRI characteristics of the substantia nigra in Parkinson's disease: a combined quantitative T1 and DTI study. Neuroimage 2009;47:435-441.
54. Ziegler DA, Wonderlick JS, Ashourian P, et al. Substantia nigra volume loss before basal forebrain degeneration in early Parkinson disease. JAMA Neurol 2013;70:241-247.
55. Menke RA, Jbabdi S, Miller KL, Matthews PM, Zarei M. Connectivity-based segmentation of the substantia nigra in human and its implications in Parkinson's disease. Neuroimage 2010;52:1175-1180.
56. Yao B, Li TQ, Gelderen P, Shmueli K, de Zwart JA, Duyn JH. Susceptibility contrast in high field MRI of human brain as a function of tissue iron content. Neuroimage 2009;44:1259-1266.
57. Cho ZH, Oh SH, Kim JM, et al. Direct visualization of Parkinson's disease by in vivo human brain imaging using 7.0T magnetic resonance imaging. Mov Disord 2011;26:713-718.
58. Kwon DH, Kim JM, Oh SH, et al. Seven-Tesla magnetic resonance images of the substantia nigra in Parkinson disease. Ann Neurol 2012;71:267-277.
59. Blazejewska AI, Schwarz ST, Pitiot A, et al. Visualization of nigrosome 1 and its loss in PD: pathoanatomical correlation and in vivo 7 T MRI. Neurology 2013;81:534-540.
60. Cosottini M, Frosini D, Pesaresi I, et al. MR imaging of the substantia nigra at 7 T enables diagnosis of Parkinson disease. Radiology 2014:131448.
61. Schwarz ST, Afzal M, Morgan PS, Bajaj N, Gowland PA, Auer DP. The 'swallow tail' appearance of the healthy nigrosome: a new accurate test of Parkinson's disease: a case-control and retrospective cross-sectional MRI study at 3T. PLoS One 2014;9:e93814.
62. Mueller C, Pinter B, Reiter E, et al. Visualization of nigrosome 1 and its loss in PD: pathoanatomical correlation and in vivo 7T MRI. Neurology 2014;82:1752.
63. Abosch A, Yacoub E, Ugurbil K, Harel N. An assessment of current brain targets for deep brain stimulation surgery with susceptibility-weighted imaging at 7 tesla. Neurosurgery 2010;67:1745-1756; discussion 1756.
64. Berg D, Lang AE, Postuma RB, et al. Changing the research criteria for the diagnosis of Parkinson's disease: obstacles and opportunities. Lancet Neurol 2013;12:514-524.
65. Garcia-Lorenzo D, Longo-Dos Santos C, Ewenczyk C, et al. The coeruleus/subcoeruleus complex in rapid eye movement sleep behaviour disorders in Parkinson's disease. Brain 2013;136:2120-2129.